Skip to main content

516-005 A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression on or after Platinum-Based Chemotherapy and Checkpoint INhibitor T

NCT03906071

A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression on or after Platinum-Based Chemotherapy and Checkpoint INhibitor Therapy (SAPPHIRE)

Associated Conditions

Lung Cancer

Principal Investigator

Sponsor

Mirati Therapeutics

This study will compare the effectiveness of sitravatinib in combination with nivolumab versus docetaxel in subjects with non-small cell lung cancer who have previously had progression on or after chemotherapy and immunotherapy.

This study is currently enrolling.